


FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : FITC ANTI-IGG PRIMARY ANTIBODY

Mat.-No./ Genisys-No. : 05267919001

Manufacturer or supplier's details

 Company : Roche Diagnostics Limited
Charles Avenue

 Address : Burgess Hill
RH15 9RY West Sussex

Telephone : +44 1444 256000

Telefax : +44 1444 256239

 Emergency telephone number : +49(0)621-759-2012 oder +49(0)621-759-4848 oder
+49(0)8856-60-2629

Emergency telephone number:

 In case of emergencies: : Health, Safety & +44 1444 256500 or +44 7802
(Roche Diagnostics Ltd.) Environment 260498

- +44 1444 256561 or +44 7710

Product Safety / Vigilance 391653

-

Toxicology 24Hr help-line: : NPIS: +44 844 892 0111

Health Advice 24Hr help-line: NHS Direct: +44 845 4647

NHS 24: +44 8454 242424

Recommended use of the chemical and restrictions on use

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION
Emergency Overview

Physical state	liquid
Colour	light brown
Odour	none

GHS Classification

Not a hazardous substance or mixture.

GHS Label element

Not a hazardous substance or mixture.

Potential Health Effects
Carcinogenicity:
IARC

No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

ACGIH	human carcinogen by IARC. No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
OSHA	No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.
NTP	No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Preparation

Hazardous components

No hazardous ingredients

SECTION 4. FIRST AID MEASURES

General advice	: Move out of dangerous area. Show this safety data sheet to the doctor in attendance. Do not leave the victim unattended.
If inhaled	: Move to fresh air. Consult a physician after significant exposure. If unconscious place in recovery position and seek medical advice.
In case of skin contact	: If on skin, rinse well with water.
In case of eye contact	: Flush eyes with water as a precaution. Remove contact lenses. Protect unharmed eye. Keep eye wide open while rinsing. If eye irritation persists, consult a specialist.
If swallowed	: Keep respiratory tract clear. Do not give milk or alcoholic beverages. Never give anything by mouth to an unconscious person. If symptoms persist, call a physician.
Notes to physician	: The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Unsuitable extinguishing media	: High volume water jet

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

- Specific hazards during firefighting : No information available.
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for firefighters : Wear self contained breathing apparatus for fire fighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Ensure adequate ventilation.
Refer to protective measures listed in sections 7 and 8.
- Environmental precautions : Prevent product from entering drains.
Prevent further leakage or spillage if safe to do so.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

- Advice on safe handling : Avoid formation of aerosol.
Do not breathe vapours/dust.
Avoid exposure - obtain special instructions before use.
Avoid contact with skin and eyes.
For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
Provide sufficient air exchange and/or exhaust in work rooms.
Dispose of rinse water in accordance with local and national regulations.
Persons susceptible to skin sensitisation problems or asthma, allergies, chronic or recurrent respiratory disease should not be employed in any process in which this mixture is being used.
- Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.
Electrical installations / working materials must comply with the technological safety standards.
- Materials to avoid :

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Components with workplace control parameters**

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

Contains no substances with occupational exposure limit values.

Personal protective equipment

- Respiratory protection : In the case of vapour formation use a respirator with an approved filter.
- Hand protection
Material : Protective gloves
- Remarks : The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. This recommendation is only valid for the product mentioned in the safety data sheet and provided by us and for the application specified by us. Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the contact time. The suitability for a specific workplace should be discussed with the producers of the protective gloves.
- Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles
- Skin and body protection : impervious clothing
Choose body protection according to the amount and concentration of the dangerous substance at the work place.
- Hygiene measures : When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : liquid
- Colour : light brown
- Odour : none
- pH : 7.7, (22 °C)
- Melting point/range : no data available
- Boiling point/boiling range : no data available
- Flash point :
does not flash
- Upper explosion limit : no data available
- Lower explosion limit : no data available
- Density : 1.005 g/cm³
- Solubility(ies)
- Water solubility : completely miscible
- Auto-ignition temperature : no data available

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

Thermal decomposition : no data available
Oxidizing properties : The substance or mixture is not classified as oxidizing.

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Reacts with the following substances:
Oxidizing agents
No decomposition if stored and applied as directed.
Conditions to avoid : no data available
Incompatible materials : no data available
Hazardous decomposition products : Carbon oxides
Sulphur oxides
nitrogen oxides (NOx)

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity****Product:**

Acute inhalation toxicity : Acute toxicity estimate : 30.03 mg/l
Exposure time: 4 h
Test atmosphere: vapour
Method: Calculation method

Skin corrosion/irritation**Product:**

Remarks: May cause skin irritation and/or dermatitis.

Serious eye damage/eye irritation**Product:**

Remarks: Vapours may cause irritation to the eyes, respiratory system and the skin.

Respiratory or skin sensitisation**Product:**

Remarks: Causes sensitisation.

Germ cell mutagenicity

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

no data available

Carcinogenicity

no data available

Reproductive toxicity

no data available

STOT - single exposure

no data available

STOT - repeated exposure

no data available

Aspiration toxicity

no data available

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Product:**

Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to
the environment : no data available**Persistence and degradability**

no data available

Bioaccumulative potential

no data available

Mobility in soil

no data available

Other adverse effects

no data available

Product:

Regulation

40 CFR Protection of Environment; Part 82 Protection of
Stratospheric Ozone - CAA Section 602 Class I Substances

Remarks

This product neither contains, nor was manufactured with a
Class I or Class II ODS as defined by the U.S. Clean Air Act
Section 602 (40 CFR 82, Subpt. A, App.A + B).

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not contaminate ponds, waterways or ditches with

**FITC ANTI-IGG PRIMARY ANTIBODY**

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

chemical or used container.
Send to a licensed waste management company.
Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty remaining contents.
Dispose of as unused product.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION**International regulation****IATA-DGR**

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADNR,
IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION

OSHA Hazards : No OSHA Hazards

WHMIS Classification : Not Rated

EPCRA - Emergency Planning and Community Right-to-Know Act

SARA 302 : SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 : SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

Clean Air Act

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 12 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM I Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

US State Regulations
Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

non hazardous compounds	Not Assigned 90 - 100 %
-------------------------	-------------------------

New Jersey Right To Know

non hazardous compounds	Not Assigned 90 - 100 %
Albumins, beef serum	94349-60-7 1 - 5 %
Animal serum /-plasma - different species	Not Assigned 1 - 5 %

California Prop 65 : This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

Inventories

AICS (Australia), DSL (Canada), IECSC (China), ENCS (Japan), ISHL (Japan), KECI (Korea), NZIoC (New Zealand), PICCS (Philippines), TSCA (USA)


SECTION 16. OTHER INFORMATION

FITC ANTI-IGG PRIMARY ANTIBODY

Version 1.1

Revision Date 11-18-2013

Print Date 04-17-2014

Further information
NFPA:

HMIS III:

HEALTH	0
FLAMMABILITY	1
PHYSICAL HAZARD	0

0 = not significant, 1 =Slight,
 2 = Moderate, 3 = High
 4 = Extreme, * = Chronic

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.